Loading clinical trials...
Loading clinical trials...
A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, Zanubrutinib, in Combination With Lenalidomide Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Conditions
Interventions
Zanubrutinib
Lenalidomide
+5 more
Locations
2
China
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, China
First affiliation hospital of nanjing medical university
Nanjing, Jiangsu, China
Start Date
February 1, 2022
Primary Completion Date
February 1, 2024
Completion Date
February 1, 2025
Last Updated
March 11, 2022
NCT05529069
NCT05006716
NCT06026319
NCT05442515
NCT03050268
NCT03938987
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions